RBC Capital Maintains Outperform on AbbVie, Raises Price Target to $330
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice TargetHot
RBC Capital analyst Trung Huynh maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $280 to $330.
RBC Capital analyst Trung Huynh maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $280 to $330.